

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
24 June 2021 (24.06.2021)



(10) International Publication Number
WO 2021/126734 A1

(51) International Patent Classification:
C12N 15/113 (2010.01) A61P 1/16 (2006.01)
A61K 31/713 (2006.01)

TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

(21) International Application Number:
PCT/US2020/064776

Declarations under Rule 4.17:

— as to applicant's entitlement to apply for and be granted a
patent (Rule 4.17(ii))

(22) International Filing Date:
14 December 2020 (14.12.2020)

Published:

— with international search report (Art. 21(3))
— before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments (Rule 48.2(h))
— with sequence listing part of description (Rule 5.2(a))

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
62/948,445 16 December 2019 (16.12.2019) US
63/040,602 18 June 2020 (18.06.2020) US

(71) Applicant: **ALNYLAM PHARMACEUTICALS, INC.**
[US/US]; 675 West Kendall Street, Henri A. Termeer
Square, Cambridge, MA 02142 (US).

(72) Inventors: **TREMBLAY, Frederic**; 675 West Kendall
Street, Henri A. Termeer Square, Cambridge, MA 02142
(US). **MCININCH, James, D.**; 675 West Kendall Street,
Henri A. Termeer Square, Cambridge, MA 02142 (US).
CASTORENO, Adam; 675 West Kendall Street, Henri
A. Termeer Square, Cambridge, MA 02142 (US). **SCH-
LEGEL, Mark, K.**; 675 West Kendall Street, Henri A. Ter-
meer Square, Cambridge, MA 02142 (US). **KAITTANIS,
Charalambos**; 675 West Kendall Street, Henri A. Termeer
Square, Cambridge, MA 02142 (US).

(74) Agent: **ZACHARAKIS, Maria, Laccotripe**; Mccarter &
English, LLP, 265 Franklin Street, Boston, MA 02110 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN,
KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD,
ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO,
NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW,
SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,

(54) Title: PATATIN-LIKE PHOSPHOLIPASE DOMAIN CONTAINING 3 (PNPLA3) RNA COMPOSITIONS AND METHODS
OF USE THEREOF

(57) Abstract: The present invention relates to RNAi agents, e.g., double stranded RNA (dsRNA) agents, targeting the Patatin-Like
Phospholipase Domain Containing 3 (PNPLA3) gene. The invention also relates to methods of using such RNAi agents to inhibit
expression of a PNPLA3 gene and to methods of preventing and treating a PNPLA3 -associated disorder, e.g., Nonalcoholic Fatty
Liver Disease (NAFLD).

WO 2021/126734 A1